BamSEC and AlphaSense Join Forces
Learn More

CNS Pharmaceuticals Inc. – Material Contracts

NASDAQ: CNSP    
Share price (3/25/26): $2.73    
Market cap (3/25/26): $1.693 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 6 pages February 27, 2026 by Email Sandra Silberman [***] [***] Re: Separation From CNS Pharmaceuticals, Inc
12/34/56
EX-10.1
from 8-K 8 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 8 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 8 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 6 pages December 16, 2025 by Email John Climaco [***] Re: Separation From CNS Pharmaceuticals, Inc
12/34/56
EX-10.1
from 8-K 7 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 12 pages CNS Pharmaceuticals, Inc. 2020 Equity Plan
12/34/56
EX-10.1
from 8-K 32 pages Securities Purchase Agreement
12/34/56
EX-10.27
from S-1 34 pages Securities Purchase Agreement
12/34/56
EX-10.27
from DRS 34 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 31 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 21 pages Stock Purchase Agreement Between Cns Pharmaceuticals, Inc., and Cortice Biosciences, Inc., Dated: July 29, 2024
12/34/56
EX-10.1
from 8-K 33 pages Exclusive License Agreement for Tpi-287 Between Cortice Biosciences, Inc. and Cns Pharmaceuticals, Inc
12/34/56
EX-10.1
from 8-K 3 pages Waiver and Consent Agreement
12/34/56
EX-10.2
from 8-K 5 pages Confidential Cns Pharmaceuticals, Inc. Attention: Christopher Downs 2100 West Loop South Suite 900 Houston, Tx 77027 the Purpose of This Financial Advisory Agreement (This “Agreement”) Is to Confirm the Engagement of A.G.P./ALLIANCE Global Partners (“A.G.P.”) by Cns Pharmaceuticals, Inc. (The “Company”) to Render Financial Services (As Defined Below) to the Company
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 6 pages June 26, 2024 Confidential the Purpose of This Financial Advisory Agreement (This “Agreement”) Is to Confirm the Engagement of A.G.P./ALLIANCE Global Partners (“A.G.P.”) by Cns Pharmaceuticals, Inc. (The “Company”) to Render Financial Services (As Defined Below) to the Company
12/34/56
EX-10.1
from 8-K 35 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 6 pages June 14, 2024 Confidential Cns Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South Suite 900 Houston, Tx 77027 the Purpose of This Financial Advisory Agreement (This “Agreement”) Is to Confirm the Engagement of A.G.P./ALLIANCE Global Partners (“A.G.P.”) by Cns Pharmaceuticals, Inc. (The “Company”) to Render Financial Services (As Defined Below) to the Company
12/34/56
EX-10.1
from 8-K 34 pages Securities Purchase Agreement
12/34/56